Genentech Doubles Holly Springs Investment to $2B, Adding 100 Jobs
Genentech, a Roche Group member, has doubled its Holly Springs investment to about $2 billion, expanding capacity for next-generation metabolic condition treatments set to be operational in 2029. The expansion will create 100 additional manufacturing jobs, support over 500 high-wage roles and 1,500 construction positions, strengthening the U.S. supply chain.
1. Genentech Doubles RHHBY’s East Coast Manufacturing Investment
Genentech, part of the Roche Group (RHHBY), has increased its commitment to its first U.S. East Coast facility in Holly Springs, North Carolina, to approximately $2 billion, more than doubling the initial investment announced in May 2025. The expanded funding will build additional biomanufacturing capacity—leveraging automation and digital tools—and enable production of next-generation therapies for metabolic conditions such as obesity. Set to begin operations by 2029, the facility will support over 500 high-wage manufacturing positions and 1,500 construction roles, and add 100 new local jobs. This move underscores Roche’s broader $50 billion pledge to strengthen domestic pharmaceutical production and diversify its U.S. supply chain, bolstering RHHBY’s long-term resilience, operational scale and ability to deliver life-changing medicines more reliably to patients.